Trial Profile
A Pilot Safety and Toxicity Trial of Adjuvant Chemotherapy With Gemcitabine and Docetaxel and Radiation Therapy for Completely Resected Uterine Leiomyosarcoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2023
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Gemcitabine (Primary)
- Indications Leiomyosarcoma
- Focus Therapeutic Use
- 10 Dec 2019 Status changed from recruiting to discontinued. Study terminated due to low accrual. PI left the institution
- 15 Oct 2013 New trial record